Факторы прогноза при первичных миелодиспластических синдромах у лиц молодого и среднего возраста
Н. Н. Климкович, Ольга Владимировна Красько, Т И Козарезова · ScienceRise · 2015
We spent multivariate analysis of clinical and laboratory parameters for the prediction of de-novo myelodysplastic syndromes (MDS) patients aged 18-60 years. The results of clinical application of prognostic systems in MDS show that there is a large variability within individual risk groups, especially at low-risk MDS. So now hematologists conduct research aimed at identifying additional adverse risk MDS. This is done so that patients with low-risk MDS embodiments and unfavorable prognosis could benefit from early therapeutic intervention, and not only be clinician monitored until disease progression. We found that additional adverse risk factors for the development of MDS are the expression of CD95 in bone marrow ≤40 % and FLT3≥60 %. The expression level of CD95 in bone marrow cells≤40 % and FLT3≥60 % can be considered as a prognostic marker progression of MDS and time start specific therapy
Cited by 0 works. doi:10.15587/2313-8416.2015.36499 Open-access PDF
Authors
References
- R: A Language and Environment for Statistical Computing
- International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
- Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
- TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
- Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
- Myelodysplastic Syndromes/Neoplasms—Overview
- WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
- Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms